Key Highlights

  • TriSalus Life Sciences (NASDAQ:TLSI) closed at USD 2.46 on Tuesday, November 10, 2026, down 23.76% from a calculated prior close of USD 3.23, among the biggest decliners in a published screener snapshot of 4,625 names.
  • The third quarter 2026 release dated November 10, 2026 showed Revenue of USD 12.9 million, up 11.3% from USD 11.6 million, and 2026 revenue guidance revised to a range of USD 46 million to USD 48 million.
  • Volume was 623.61K shares, a relative Volume of 4.11, worth about USD 1.53 million at the close (calculated), and the snapshot shows a Market Value of USD 151.17 million.
  • Cash was USD 41.1 million on September 30, 2026, against a quarterly net loss of USD 8.9 million, or USD 0.15 per share, versus a loss of USD 0.96 per share a year earlier.

What Moved TriSalus Life Sciences on November 10 (-23.76%)

The shares of the medical technology company ended the regular session at USD 2.46, down 23.76%. Simple arithmetic gives a calculated prior close of USD 3.23 for Monday, November 9, 2026, a loss of about USD 0.77 per share. Volume of 623.61K shares at a relative volume of 4.11 implies an average near 151.7K shares (calculated), so turnover ran about four times the norm. The snapshot lists trailing diluted EPS of USD -1.30, EPS growth of -9.89%, no P/E and a Dividend Yield of 0.00%. The company filed its third quarter 2026 Earnings release as an 8-K dated November 10, 2026. Whether it reached the market before the open, during the session or after the close is not confirmed here, so the link between the release and the fall is an inference, not a stated cause.

The Rationale: Third Quarter Results and Revised Guidance

The identified catalyst is the results release. Third quarter 2026 revenue was USD 12.9 million, up 11.3%, with gross Margin of 86.2% against 83.5%. Net loss was USD 8.9 million, or USD 0.15 per share, compared with USD 41.3 million, or USD 0.96 per share, attributable to common stockholders a year earlier, which included about USD 30.5 million tied to a preferred stock conversion. Adjusted EBITDA loss was USD 4.7 million versus USD 5.4 million. Full-year 2026 revenue guidance was revised to USD 46 million to USD 48 million, about 2% to 6% growth. Nine-month revenue of USD 33.2 million means the fourth quarter must deliver USD 12.8 million to USD 14.8 million to meet the range (calculated). As general context, a revised outlook can reset expectations quickly, but that is a general mechanism, not a confirmed cause.

Valuation, Liquidity and Risks for TriSalus Life Sciences

The market value of USD 151.17 million compares with 61,659,370 shares outstanding on September 30, 2026, which gives about USD 151.7 million at USD 2.46 (calculated), so the figures reconcile. Against the guidance midpoint of USD 47 million, that is about 3.2 times sales (calculated). Cash of USD 41.1 million follows a USD 46.0 million gross Equity offering in the first quarter of 2026. Sales and Marketing expense rose to USD 10.7 million from USD 6.8 million, which keeps the loss large. Specific risks include another equity raise and dilution, execution against a back-weighted fourth-quarter target, and a price that moved 23.76% in one session. Liquidity is modest, so a small number of trades can move the price and spreads can widen. Nothing here suggests the move will continue.

Where Things Stand

TriSalus Life Sciences (NASDAQ:TLSI) fell 23.76% to USD 2.46 on November 10, 2026, the day it published third quarter results and a revised 2026 revenue range of USD 46 million to USD 48 million. The timing of the release against the session is not confirmed, so the link is an inference.